Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
John Celebi

John Celebi

President and CEO, Sensei Biotherapeutics

Appears in 1 story

Notable Quotes

"After careful review of future funding needs and the current capital markets environment, we have determined not to initiate a new clinical study." — John Celebi on solnerstotug discontinuation, October 2025

Stories

Multi-node PI3K inhibition reaches clinical testing

New Capabilities

Leading combined company post-acquisition

Lewis Cantley discovered the PI3K enzyme in 1985. Four decades later, a combination therapy targeting multiple nodes of the pathway he uncovered just demonstrated an 80% response rate in endometrial cancer patients—triple the historical rate with chemotherapy alone. Sensei Biotherapeutics acquired Faeth Therapeutics and raised $200 million to push this approach through pivotal trials.

Updated 2 hours ago